The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
NCT05102292 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2023-08-21
Summary
The purpose of this study was to assess efficacy, safety and PK in anaplastic thyroid cancer (ATC) given HLX208 (BRAF V600E inhibitor).
Conditions
- Anaplastic Thyroid Cancer
- ATC
Interventions
- DRUG
-
HLX208
HLX208 450mg bid po
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-10
- Primary Completion
- 2024-06-30
- Completion
- 2024-12-30
Countries
- China
Study Locations
More Related Trials
-
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
NCT05360368 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
NCT05513573 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
NCT06062563 ·Status: UNKNOWN ·Phase: NA
-
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
NCT04309136 ·Status: UNKNOWN ·Phase: PHASE2
-
Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer
NCT04521348 ·Status: COMPLETED ·Phase: PHASE2
-
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
NCT05659186 ·Status: RECRUITING ·Phase: PHASE2
-
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
NCT06725498 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
NCT06839066 ·Status: RECRUITING ·Phase: PHASE2
-
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma
NCT03618238 ·Status: COMPLETED ·Phase: PHASE2
-
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
NCT06554028 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
NCT05263986 ·Status: UNKNOWN ·Phase: PHASE1
-
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
NCT06195228 ·Status: RECRUITING ·Phase: PHASE4
-
Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
NCT00677118 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
NCT06359847 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
NCT04280081 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
NCT05343325 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
NCT06223308 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
NCT06374602 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma
NCT05232552 ·Status: UNKNOWN ·Phase: PHASE2
-
Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
NCT04926753 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of TFX05-01 in Patients With Advanced Solid Tumors
NCT05434299 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
NCT05400265 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
NCT05830500 ·Status: RECRUITING ·Phase: PHASE4
-
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
NCT06908434 ·Status: RECRUITING ·Phase: PHASE1